Regen Med recently executed inCytes™ license and related agreements with the Galeazzi Orthopedic Institute (“IOG”), one of the largest orthopedic research/clinical centers in Europe. IOG in turn is one of 18 hospitals owned by Gruppo San Donato (“GSD”) — 4 million patients annually, 5,100 beds, 4,000 physicians.
Using inCytes™ as the backbone, IOG and GSD are consolidating under a separate brand — “REGAIN” — the development, standardization and delivery of regenerative medicine procedures. REGAIN is scheduled to commence operations this September in orthopedic, oral and plastic/reconstructive surgery, as well as physiatry and sports medicine. Expansion of REGAIN activities to other disciplines will follow shortly thereafter.
Regen Med will provide a number of services to support REGAIN, including clinical data collection and reports, education and training, coordination with vendors, studies/trials, payor reimbursement, product incubation and international patient referrals.
For additional information, please refer to our Corporate Literature page, or contact us at email@example.com.